Association between a regional reimbursement policy and treatment escalation in pulmonary arterial hypertension: a real-world cohort study with long-term Markov cost-effectiveness analysis.

Xie Y, Chen Y, Luo J, Chen J, Tan Y, Wang T, Chen W, Li J

Open source

DOI
10.3389/fphar.2026.1892453
Published
2026
Container
Frontiers in pharmacology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2026.1892453,
  title = {Association between a regional reimbursement policy and treatment escalation in pulmonary arterial hypertension: a real-world cohort study with long-term Markov cost-effectiveness analysis.},
  author = {Xie Y and Chen Y and Luo J and Chen J and Tan Y and Wang T and Chen W and Li J},
  year = {2026},
  journal = {Frontiers in pharmacology},
  doi = {10.3389/fphar.2026.1892453},
  url = {https://doi.org/10.3389/fphar.2026.1892453}
}

RIS

TY  - JOUR
TI  - Association between a regional reimbursement policy and treatment escalation in pulmonary arterial hypertension: a real-world cohort study with long-term Markov cost-effectiveness analysis.
AU  - Xie Y
AU  - Chen Y
AU  - Luo J
AU  - Chen J
AU  - Tan Y
AU  - Wang T
AU  - Chen W
AU  - Li J
PY  - 2026
JO  - Frontiers in pharmacology
DO  - 10.3389/fphar.2026.1892453
UR  - https://doi.org/10.3389/fphar.2026.1892453
ER  - 

APA

Y, X., Y, C., J, L., J, C., Y, T., T, W., W, C., & J, L. (2026). Association between a regional reimbursement policy and treatment escalation in pulmonary arterial hypertension: a real-world cohort study with long-term Markov cost-effectiveness analysis.. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2026.1892453

Source records